EP1267870A2 - Inhibition of cytokine generation - Google Patents

Inhibition of cytokine generation

Info

Publication number
EP1267870A2
EP1267870A2 EP01928407A EP01928407A EP1267870A2 EP 1267870 A2 EP1267870 A2 EP 1267870A2 EP 01928407 A EP01928407 A EP 01928407A EP 01928407 A EP01928407 A EP 01928407A EP 1267870 A2 EP1267870 A2 EP 1267870A2
Authority
EP
European Patent Office
Prior art keywords
desloratadine
allergic
basophils
inhibition
generation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01928407A
Other languages
German (de)
English (en)
French (fr)
Inventor
Robert P. Schleimer
John Schroeder
William Kreutner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of EP1267870A2 publication Critical patent/EP1267870A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP01928407A 2000-04-07 2001-04-05 Inhibition of cytokine generation Withdrawn EP1267870A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19601600P 2000-04-07 2000-04-07
US196016P 2000-04-07
PCT/US2001/011474 WO2001076600A2 (en) 2000-04-07 2001-04-05 Inhibition of cytokine generation

Publications (1)

Publication Number Publication Date
EP1267870A2 true EP1267870A2 (en) 2003-01-02

Family

ID=22723784

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01928407A Withdrawn EP1267870A2 (en) 2000-04-07 2001-04-05 Inhibition of cytokine generation

Country Status (6)

Country Link
EP (1) EP1267870A2 (es)
JP (1) JP2003530351A (es)
AU (1) AU2001255268A1 (es)
CA (1) CA2405413A1 (es)
MX (1) MXPA02009821A (es)
WO (1) WO2001076600A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192261A1 (en) * 2003-09-15 2005-09-01 Jost-Price Edward R. Methods and reagents for the treatment of immunoinflammatory disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595997A (en) * 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0176600A2 *

Also Published As

Publication number Publication date
MXPA02009821A (es) 2003-03-27
AU2001255268A1 (en) 2001-10-23
CA2405413A1 (en) 2001-10-18
WO2001076600A3 (en) 2002-06-27
JP2003530351A (ja) 2003-10-14
WO2001076600A2 (en) 2001-10-18

Similar Documents

Publication Publication Date Title
Du Buske Clinical comparison of histamine H1–receptor antagonist drugs
Grant et al. Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial
US20030229030A1 (en) Method of treating interleukin-6-mediated inflammatory diseases
Hurst et al. Ebastine: an update of its use in allergic disorders
Murdoch et al. Desloratadine: an update of its efficacy in the management of allergic disorders
Keam et al. Rupatadine: a review of its use in the management of allergic disorders
US20060276495A1 (en) Treatment methods of nasal congestion and nasal obstruction
US20080262018A1 (en) Treating allergic and inflammatory conditions
Terrien et al. Comparison of the effects of terfenadine with fexofenadine on nasal provocation tests with allergen
Rendi-Wagner et al. Unexpected frequency, duration and spectrum of adverse events after therapeutic dose of mefloquine in healthy adults
US6599914B2 (en) Inhibition of cytokine generation
Archana et al. Antipyretic and analgesic activities of Caesalpinia bonducella seed kernel extract
CN107635564B (zh) 人参皂苷m1用于预防或治疗硅肺病的用途
TW202333726A (zh) 以ｓｓａｏ抑制劑治療肝病
Day Pros and cons of the use of antihistamines in managing allergic rhinitis
WO2001074365A2 (en) An efficacious dosage regimen of galantamine that reduces side effects
WO2001076600A2 (en) Inhibition of cytokine generation
WO2008058033A2 (en) Soluble epoxide hydrolase inhibitors for the treatment of rheumatoid arthritis
Lordan et al. H1-antihistamines in asthma
Borade et al. Modern H1-antihistamines in asthma
Vivero et al. A close look at fenfluramine and dexfenfluramine
Lotrich et al. Dextromethorphan-induced delirium and possible methadone interaction
Ibrahim et al. Study of the correlation between clozapine levels and clinical findings in acutely intoxicated patients admitted to poison control Center-Ain Shams University hospitals: 6 months (a prospective study)
Sorensen et al. Low-level resistance to camptothecin in a human small-cell lung cancer cell line without reduction in DNA topoisomerase I or drug-induced cleavable complex formation
Davis et al. Muscarinic Receptor Antagonism and Allergen Induced Airway Responses in Allergic Asthma: A Scoping Review

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO PAYMENT 20021018;SI PAYMENT 20021018

17P Request for examination filed

Effective date: 20021018

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051102